Literature DB >> 1430106

Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures.

J C Beckham1, D S Caldwell, B L Peterson, A M Pippen, M S Currie, F J Keefe, J B Weinberg.   

Abstract

Rheumatoid arthritis is a complex inflammatory disease of unknown cause. Although various laboratory and clinical measurements are useful in managing these patients, there is a need for better tests to quantitatively assess disease activity. The purpose of this study was to investigate the association of certain immune and inflammation (I-I) parameters with four traditional disease severity measures and a functional measure in rheumatoid arthritis patients. A single set of patient blood samples was analyzed, and four traditional disease severity measures and patient functional statuses were determined from 64 consecutive outpatients with rheumatoid arthritis. Plasma tumor necrosis factor-alpha (TNF), soluble interleukin-2 receptor (sIL-2R), sCD4 and sCD8 (and the sCD4/sCD8 ratio), neopterin, and fibrin D-dimer were analyzed in relationship to Westergren erythrocyte sedimentation rate (ESR), physician assessment of disease activity, joint pain count, grip strength, and Arthritis Impact Measurement Scale (AIMS) scores. Rheumatoid arthritis patients had higher mean levels of all I-I measures (except sCD4) compared to healthy subjects. Initial significant correlations between TNF, sIL-2R, and D-dimer and several disease severity and functional measures were detected. When we controlled for the covariates age, gender, race, and medications, regression analyses indicated that, as a group, the I-I measures were significantly related to grip strength, physician disease severity rating, ESR, and total joint pain. When the predictive values of the I-I measures were tested controlling for the covariates and ESR, D-dimer was independently and significantly associated with variability in grip strength, physician disease severity, and AIMS physical disability, while TNF was associated with a significant amount of variability in total joint pain.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430106     DOI: 10.1007/bf00920793

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  40 in total

Review 1.  Assessment of disease activity in rheumatoid arthritis.

Authors:  N J Olsen
Journal:  Curr Opin Rheumatol       Date:  1989-06       Impact factor: 5.006

2.  Regulation of T cell clone function via CD4 and CD8 molecules. Anti-CD4 can mediate two distinct inhibitory activities.

Authors:  M L Blue; D A Hafler; J F Daley; H Levine; K A Craig; J B Breitmeyer; S F Schlossman
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

3.  Outcome assessment in clinical trials. Evidence for the sensitivity of a health status measure.

Authors:  R F Meenan; J J Anderson; L E Kazis; M J Egger; M Altz-Smith; C O Samuelson; R F Willkens; M A Solsky; S P Hayes; K L Blocka
Journal:  Arthritis Rheum       Date:  1984-12

4.  Effects of recombinant human interleukin-1 beta on rabbit articular chondrocytes. Stimulation of prostanoid release and inhibition of cell growth.

Authors:  J E Chin; Y A Lin
Journal:  Arthritis Rheum       Date:  1988-10

5.  Urinary neopterin index as a measure of rheumatoid activity.

Authors:  P Hannonen; S Tikanoja; M Hakola; T Möttönen; L Viinikka; M Oka
Journal:  Scand J Rheumatol       Date:  1986       Impact factor: 3.641

6.  Function of the CD4 and CD8 molecules on human cytotoxic T lymphocytes: regulation of T cell triggering.

Authors:  B Fleischer; H Schrezenmeier; H Wagner
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

7.  Abnormal distribution of the helper-inducer and suppressor-inducer T-lymphocyte subsets in the rheumatoid joint.

Authors:  C Pitzalis; G Kingsley; J Murphy; G Panayi
Journal:  Clin Immunol Immunopathol       Date:  1987-11

8.  Measurement of cross linked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies.

Authors:  A N Whitaker; M J Elms; P P Masci; P G Bundesen; D B Rylatt; A J Webber; I H Bunce
Journal:  J Clin Pathol       Date:  1984-08       Impact factor: 3.411

9.  Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.

Authors:  C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

10.  Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.

Authors:  J M Dayer; B Beutler; A Cerami
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  24 in total

Review 1.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

2.  Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Young Hee Rho; Joseph Solus; Paolo Raggi; Annette Oeser; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

3.  Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis.

Authors:  Helmut Wittkowski; Dirk Foell; Erik af Klint; Leen De Rycke; Filip De Keyser; Michael Frosch; Ann-Kristin Ulfgren; Johannes Roth
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

4.  Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis.

Authors:  P Lamprecht; F Moosig; A Gause; K Herlyn; E Csernok; H Hansen; W L Gross
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 5.  Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.

Authors:  Christine R Culy; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Etanercept: a review of its use in rheumatoid arthritis.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

7.  Serum level of neopterin is not a marker of disease activity in treated rheumatoid arthritis patients.

Authors:  Dalia El-Lebedy; Jihan Hussein; Ingy Ashmawy; Asmaa M Mohammed
Journal:  Clin Rheumatol       Date:  2016-10-03       Impact factor: 2.980

8.  TNF signals via neuronal-type nitric oxide synthase and reactive oxygen species to depress specific force of skeletal muscle.

Authors:  Shawn A Stasko; Brian J Hardin; Jeffrey D Smith; Jennifer S Moylan; Michael B Reid
Journal:  J Appl Physiol (1985)       Date:  2013-04-04

9.  Evaluation of plasma D-dimer plus fibrinogen in predicting acute CVST.

Authors:  Ran Meng; Xiaoying Wang; Mohammed Hussain; David Dornbos; Lu Meng; Yu Liu; Yan Wu; Mingming Ning; Buonanno Ferdinando S; Eng H Lo; Yuchuan Ding; Xunming Ji
Journal:  Int J Stroke       Date:  2013-03-19       Impact factor: 5.266

10.  Serum soluble markers in the evaluation of treatment in human visceral leishmaniasis.

Authors:  A Schriefer; A Barral; E M Carvalho; M Barral-Netto
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.